mTLS status predicts survival benefit from adjuvant chemotherapy in gastric cancer patients treated with neoadjuvant therapy and surgery
Dan Liu, Chenyu Tian, Bosen Li, Xinyou Liu, Chengbo Ji, Yihong Sun, Junjie Zhao, Haojie Li, Xuefei Wang · 2025
Read mTLS status predicts survival benefit from adjuvant chemotherapy in gastric cancer patients treated with neoadjuvant therapy and surgery by Dan Liu, Chenyu Tian, Bosen Li, Xinyou Liu, Chengbo Ji, Yihong Sun, Junjie Zhao, Haojie Li, Xuefei Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780721.txt.
Description
Dan Liu and co-authors ask whether more chemotherapy after surgery helps stomach cancer patients who already had it before surgery, in a 2025 study. The team reviewed records of patients who had drug treatment, then radical surgery. After matching like with like, 180 patients remained: 116 who got further chemotherapy and 64 who did not. Overall survival did not differ between the groups.
No subgroup by tumor depth, spread, or response gained from the extra drugs either. One tissue feature changed the story: mature tertiary lymphoid structures in the tumor bed. Patients lacking them lived longer with the extra chemotherapy, while patients who had them did better without it. Statistical tests confirmed the treatment effect hinged on that feature. The authors propose it as a guide for who should get more treatment.
Catalog record
| CREATOR | Dan Liu, Chenyu Tian, Bosen Li, Xinyou Liu, Chengbo Ji, Yihong Sun, Junjie Zhao, Haojie Li, Xuefei Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |